Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 52

Sort by

Sort Order Select

Journal Articles

A Single Center Retrospective Analysis of Daratumumab, Pomalidomide, and Dexamethasone As a Second Line Therapy for Multiple Myeloma

Lawrence Liu, MD, Gao Feng, MD PhD MPH, Mark A. Fiala, MSW, Justin King, BS, Scott R. Goldsmith, MD, Tanya M. Wildes, MD MSCI, Keith E. Stockerl-Goldstein, MD, Ravi Vij, MBBS, Mark A. Schroeder, MD

Blood (2020) 136 (Supplement 1): 31–32.

https://doi.org/10.1182/blood-2020-137023

Published: 2020

Journal Articles

Comparison of Outcomes after Haploidentical Relative and HLA Matched Unrelated Donor Transplantation with Post-Transplant Cyclophosphamide Containing Gvhd Prophylaxis Regimens

Blood (2020) 136 (Supplement 1): 21–22.

https://doi.org/10.1182/blood-2020-137221

Published: 2020

Journal Articles

A Single-Arm, Open-Label Phase 1 Study of Itacitinib (ITA) with Calcineurin Inhibitor (CNI)-Based Interventions for Prophylaxis of Graft-Versus-Host Disease (GVHD; GRAVITAS-119)

Hannah Choe, MD, Nirav N. Shah, MD, Patrice Chevallier, MD PhD, Marie Thérèse Rubio, MD PhD, Mark A. Schroeder, MD, Nancy M. Hardy, MD, Patrick J. Stiff, MD, Carlos Solano, MD PhD, Ibrahim Yakoub-Agha, Jonathan A. Gutman, MD, Scott D. Rowley, MD, Maria Caterina Mico', MD, Elisabetta Terruzzi, MD, Rafael F. Duarte, MD PhD FRCP, Rodica Morariu-Zamfir, MD, Michael Arbushites, Kai Ding, PhD, Miguel-Angel Perales, MD

Blood (2020) 136 (Supplement 1): 50–51.

https://doi.org/10.1182/blood-2020-140747

Published: 2020

Journal Articles

The Ire of IRE1α: Overexpression of IRE1α at Myeloma Diagnosis Is Associated with Decreased Survival While Downregulation of IRE1α Expression Is Predictive of Therapy Resistance

Scott R. Goldsmith, MD, Mark A. Fiala, BS, Mark A. Schroeder, MD, Tanya M. Wildes, MD, Armin Ghobadi, MD, Ravi Vij, MBBS, Keith E. Stockerl-Goldstein, MD

Blood (2019) 134 (Supplement_1): 4351.

https://doi.org/10.1182/blood-2019-131135

Published: 2019

Journal Articles

Updated Study Results of CX-01, an Inhibitor of CXCL12/CXCR4, and Azacitidine for the Treatment of Hypomethylating Agent Refractory AML and MDS

Eric Huselton, MD, Amanda F Cashen, MD, John F. DiPersio, MD PhD, Meagan Jacoby, MD, Iskra Pusic, MD, Rizwan Romee, MD PhD, Mark A. Schroeder, MD, Geoffrey L. Uy, MD, Peter Westervelt, MD PhD

Blood (2019) 134 (Supplement_1): 3915.

https://doi.org/10.1182/blood-2019-132065

Published: 2019

Journal Articles

Utilization of Autologous Stem Cell Transplantation in Older Patients with Newly Diagnosed Multiple Myeloma

Justin King, Mark A. Fiala, BS, Scott R. Goldsmith, MD, Keith E. Stockerl-Goldstein, MD, Mark A. Schroeder, MD, Armin Ghobadi, MD, Ravi Vij, MBBS, Tanya M. Wildes, MD

Blood (2019) 134 (Supplement_1): 5701.

https://doi.org/10.1182/blood-2019-130689

Published: 2019

Journal Articles

The Effect of Maintenance Therapy Following Salvage Autologous Stem Cell Transplant in Multiple Myeloma Patients

Brandon B. Wang, Mark A. Fiala, BS, Mark A. Schroeder, MD, Tanya Wildes, MD, Armin Ghobadi, MD, Keith E. Stockerl-Goldstein, MD, Ravi Vij, MBBS

Blood (2018) 132 (Supplement 1): 3439.

https://doi.org/10.1182/blood-2018-99-111379

Published: 2018

Journal Articles

Results from REACH1, a Single-Arm Phase 2 Study of Ruxolitinib in Combination with Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Vs-Host Disease

Madan Jagasia, MD MS, Miguel-Angel Perales, MD, Mark A Schroeder, MD, Haris Ali, MD, Nirav N Shah, MD, Yi-Bin Chen, MD, Michael C. Arbushites, Fitzroy Dawkins, MD, Chuan Tian, PhD, Hanna Jean Khoury, MD FACP

Blood (2018) 132 (Supplement 1): 601.

https://doi.org/10.1182/blood-2018-99-116342

Published: 2018

Journal Articles

Improving Risk Assessment of AML with a Precision Genomic Strategy to Assess Mutation Clearance

Blood (2018) 132 (Supplement 1): 5277.

https://doi.org/10.1182/blood-2018-99-114979

Published: 2018

Journal Articles

The Characteristics, Treatment Patterns, and Outcomes of Older Adults with Multiple Myeloma

Mark A. Fiala, BS, Tanya M. Wildes, MD MSCI, Mark A. Schroeder, MD, Armin Ghobadi, MD, Keith E. Stockerl-Goldstein, MD, Ravi Vij, MBBS

Blood (2018) 132 (Supplement 1): 4463.

https://doi.org/10.1182/blood-2018-99-118660

Published: 2018

Journal Articles

Increasing Daratumumab Frequency As a Way to Restore Responses- a Retrospective Case Study

Angela Vickroy, ANP, Adam Kent Peery, BS,ANP, Mark A. Fiala, BS, Tanya M. Wildes, MD MSCI, Mark A. Schroeder, MD, Armin Ghobadi, MD, Keith E. Stockerl-Goldstein, MD, Ravi Vij, MBBS

Blood (2018) 132 (Supplement 1): 5666.

https://doi.org/10.1182/blood-2018-99-119589

Published: 2018

Journal Articles

Bendamustine in Patients with Quad- and Penta-Refractory Multiple Myeloma

Scott Goldsmith, MD, Mark A. Fiala, BS, Brandon B. Wang, Mark A. Schroeder, MD, Tanya M. Wildes, MD MSCI, Armin Ghobadi, MD, Keith E. Stockerl-Goldstein, MD, Ravi Vij, MBBS

Blood (2018) 132 (Supplement 1): 5627.

https://doi.org/10.1182/blood-2018-99-112258

Published: 2018

Journal Articles

Disparities in Healthcare Resource Utilization for Multiple Myeloma

Mark A. Fiala, BS, Tanya M. Wildes, MD MSCI, Mark A. Schroeder, MD, Armin Ghobadi, MD, Keith E. Stockerl-Goldstein, MD, Ravi Vij, MBBS

Blood (2018) 132 (Supplement 1): 4793.

https://doi.org/10.1182/blood-2018-99-118392

Published: 2018

Journal Articles

A Study of Tbo-Filgrastim (Granix) to Disrupt the Bone Marrow Microenvironment in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation

Meagan Jacoby, MD, Reetom Bera, Theresa Fletcher, Mark A. Fiala, BS, Kathryn Trinkaus, PhD, John F. DiPersio, MD PhD, Keith E. Stockerl-Goldstein, MD, Mark A. Schroeder, MD, Daniel C. Link, MD, Ravi Vij, MBBS

Blood (2018) 132 (Supplement 1): 2146.

https://doi.org/10.1182/blood-2018-99-115603

Published: 2018

Journal Articles

D.C.E.P. in Patients with Quad- or Penta-Refractory Multiple Myeloma

Scott Goldsmith, MD, Mark A. Fiala, BS, Brandon B. Wang, Mark A. Schroeder, MD, Tanya M. Wildes, MD MSCI, Armin Ghobadi, MD, Keith E. Stockerl-Goldstein, MD, Ravi Vij, MBBS

Blood (2018) 132 (Supplement 1): 2021.

https://doi.org/10.1182/blood-2018-99-117713

Published: 2018

Journal Articles

A Phase 1b Study of Oprozomib with Dexamethasone or Pomalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma

Parameswaran Hari, MBBS, MD, Mark A. Schroeder, MD, James R Berenson, Andrzej Jakubowiak, MD PhD, Jonathan L Kaufman, MD, Peter M. Voorhees, MD, Hisaki Fujii, Zhao Yang, Francesco Galimi, MDPhD, Kenneth H. Shain, MD PhD

Blood (2018) 132 (Supplement 1): 803.

https://doi.org/10.1182/blood-2018-99-112610

Published: 2018

Journal Articles

Clinical Characteristics of Isolated CNS Relapse after Allogeneic Transplantation for AML — Poor Outcomes Despite Longer Time to Relapse

Pavan Kumar Bhamidipati, MBBS, MD, Armin Ghobadi, MD, Han Se-Young, MD, Shivaprasad Manjappa, MD, Feng Gao, PhD, Peter Westervelt, MDPhD, Geoffrey L. Uy, MD, Camille N. Abboud, MD, Mark A. Schroeder, MD, John F DiPersio, MD PhD

Blood (2017) 130 (Supplement 1): 4566.

https://doi.org/10.1182/blood.V130.Suppl_1.4566.4566

Published: 2017

Journal Articles

FLT3 Positivity Is a Predictor of Early Relapse Post-Transplantation — Allo-HCT Is an Ineffective Salvage Strategy in Active AML

Pavan Kumar Bhamidipati, MBBS, MD, Han Se-Young, MD, Shivaprasad Manjappa, MD, Feng Gao, PhD, Mark A. Schroeder, MD, Ravi Vij, MDMBA, Amanda F. Cashen, MD, Camille N. Abboud, MD, John F DiPersio, MD PhD

Blood (2017) 130 (Supplement 1): 4567.

https://doi.org/10.1182/blood.V130.Suppl_1.4567.4567

Published: 2017

Journal Articles

Selinexor in Combination with Cladribine, Cytarabine and G-CSF for Relapsed or Refractory AML

Geoffrey L. Uy, MD, Michael P Rettig, PhD, Theresa Fletcher, Peter A Riedell, MD, Keith E. Stockerl-Goldstein, MD, Armin Ghobadi, MD, Meagan Jacoby, MD PhD, Amanda F. Cashen, MD, Rizwan Romee, MD, Iskra Pusic, MD, Camille N. Abboud, MD, Mark A. Schroeder, MD, Ravi Vij, MDMBA, Peter Westervelt, MDPhD, John F DiPersio, MD PhD

Blood (2017) 130 (Supplement 1): 816.

https://doi.org/10.1182/blood.V130.Suppl_1.816.816

Published: 2017

Journal Articles

A Cost-Benefit Analysis of Bortezomib, Lenalidomide, and Bortezomib/Lenalidomide Combination Therapy for Newly Diagnosed Multiple Myeloma

Mark A. Fiala, BS, Tanya M. Wildes, MDMSCI, Gunjan L. Shah, MD, Armin Ghobadi, MD, Mark A. Schroeder, MD, Keith E. Stockerl-Goldstein, MD, Ravi Vij, MDMBA

Blood (2017) 130 (Supplement 1): 3108.

https://doi.org/10.1182/blood.V130.Suppl_1.3108.3108

Published: 2017

NARROW

A Single Center Retrospective Analysis of Daratumumab, Pomalidomide, and Dexamethasone As a Second Line Therapy for Multiple Myeloma

Comparison of Outcomes after Haploidentical Relative and HLA Matched Unrelated Donor Transplantation with Post-Transplant Cyclophosphamide Containing Gvhd Prophylaxis Regimens

A Single-Arm, Open-Label Phase 1 Study of Itacitinib (ITA) with Calcineurin Inhibitor (CNI)-Based Interventions for Prophylaxis of Graft-Versus-Host Disease (GVHD; GRAVITAS-119)

The Ire of IRE1α: Overexpression of IRE1α at Myeloma Diagnosis Is Associated with Decreased Survival While Downregulation of IRE1α Expression Is Predictive of Therapy Resistance

Updated Study Results of CX-01, an Inhibitor of CXCL12/CXCR4, and Azacitidine for the Treatment of Hypomethylating Agent Refractory AML and MDS

Utilization of Autologous Stem Cell Transplantation in Older Patients with Newly Diagnosed Multiple Myeloma

The Effect of Maintenance Therapy Following Salvage Autologous Stem Cell Transplant in Multiple Myeloma Patients

Results from REACH1, a Single-Arm Phase 2 Study of Ruxolitinib in Combination with Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Vs-Host Disease

Improving Risk Assessment of AML with a Precision Genomic Strategy to Assess Mutation Clearance

The Characteristics, Treatment Patterns, and Outcomes of Older Adults with Multiple Myeloma

Increasing Daratumumab Frequency As a Way to Restore Responses- a Retrospective Case Study

Bendamustine in Patients with Quad- and Penta-Refractory Multiple Myeloma

Disparities in Healthcare Resource Utilization for Multiple Myeloma

A Study of Tbo-Filgrastim (Granix) to Disrupt the Bone Marrow Microenvironment in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation

D.C.E.P. in Patients with Quad- or Penta-Refractory Multiple Myeloma

A Phase 1b Study of Oprozomib with Dexamethasone or Pomalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma

Clinical Characteristics of Isolated CNS Relapse after Allogeneic Transplantation for AML — Poor Outcomes Despite Longer Time to Relapse

FLT3 Positivity Is a Predictor of Early Relapse Post-Transplantation — Allo-HCT Is an Ineffective Salvage Strategy in Active AML

Selinexor in Combination with Cladribine, Cytarabine and G-CSF for Relapsed or Refractory AML

A Cost-Benefit Analysis of Bortezomib, Lenalidomide, and Bortezomib/Lenalidomide Combination Therapy for Newly Diagnosed Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only